Geneviève
Geneviève Almouzni, Neuilly Sur Seine FR
Patent application number | Description | Published |
---|---|---|
20120046190 | HP1ALPHA AS A PROGNOSTIC MARKER IN HUMAN CANCER - The present invention provides a prognostic marker in human cancer, HP1α, a high expression thereof being associated with a poor prognosis. The present invention further provides a method for diagnosing a cancer in a subject, HP1α a being specifically overexpressed in tumoral cells. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy and a method for monitoring the response of a subject affected with a cancer to a treatment. | 02-23-2012 |
Geneviève Bossy, Amberieu En Bugey FR
Patent application number | Description | Published |
---|---|---|
20130084598 | Method for Detecting Clusters of Biological Particles - The invention relates to a method for detecting clusters of biological particles ( | 04-04-2013 |
Geneviève Bourdy, Ramonville Saint Agne FR
Patent application number | Description | Published |
---|---|---|
20120149767 | Connection Device for a Submersible Connector - The invention relates to a device ( | 06-14-2012 |
Geneviève Choquet-Kastylevsky, Francheville FR
Patent application number | Description | Published |
---|---|---|
20110293636 | Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf - A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer. | 12-01-2011 |
20120129200 | PRODEFENSIN-A6 ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumour marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer. | 05-24-2012 |
20130171173 | METHOD FOR PRONGF ASSAY FOR IN VITRO DIAGNOSIS OF CANCER IN PARTICULAR BREAST, THYROID OR LUNG CANCER AND THERAPEUTIC USE OF PRONGF - A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer. | 07-04-2013 |
Geneviève Estenne-Bouhtou, Paris FR
Patent application number | Description | Published |
---|---|---|
20120029027 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME - The invention relates to a compound of the general formula (I), where: R is a hydrogen atom or a group selected from the (C | 02-02-2012 |
Geneviève Guedeney, Manosque FR
Patent application number | Description | Published |
---|---|---|
20110212502 | [NiFe]-Hydrogenases Having an Improved Resistance to Dioxygen, Process for Obtaining Them and Their Applications - The invention relates to [NiFe]-hydrogenases having an improved resistance to dioxygen, said [NiFe]-hydrogenases may be obtained by:—providing an initial polynucleotide comprising a sequence encoding a large subunit of a [NiFe]-hydrogenase, said large subunit comprising the following peptide motifs: L1: RGXE, wherein X=L, I, F, V or M L2: [R/K]X | 09-01-2011 |
Geneviève Gueguen-Dorbes, Paris FR
Patent application number | Description | Published |
---|---|---|
20130273049 | ROBO1-FC FUSION PROTEIN FOR USE IN THE TREATMENT OF HEPATOCARCINOMA - The present invention relates to the use a Robo1-Fc recombinant protein for treating cancer, in particular hepatocarcinoma. | 10-17-2013 |
Geneviève Inchauspe, Lyon FR
Patent application number | Description | Published |
---|---|---|
20110020398 | Novel peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus - The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods. | 01-27-2011 |
20120251569 | COMPOSITION FOR TREATING HBV INFECTION - The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections. | 10-04-2012 |
20130011435 | COMPOSITION FOR TREATING HBV INFECTION - The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections. | 01-10-2013 |
Geneviève Inchauspe, Lyon FR
Patent application number | Description | Published |
---|---|---|
20080241259 | Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof - The present invention relates to a method for preparing nonlamellar bioresorbable microparticles to which protein substances are bonded, characterized in that it comprises the steps of: | 10-02-2008 |
20090075879 | Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus - The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID No1, a peptide B having at least the amino acid sequence of SEQ ID No45, a peptide C having at least the amino acid sequence of SEQ ID No127, and a peptide D having at least the amino acid sequence of SEQ ID No 174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus. | 03-19-2009 |
20090087449 | Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus - The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID NO 1, a peptide B having at least the amino acid sequence of SEQ ID NO 45, a peptide C having at least the amino acid sequence of SEQ ID NO 127, and a peptide D having at least the amino acid sequence of SEQ ID NO 174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus. | 04-02-2009 |
20090104188 | ANTI-HEPATITIS C VIRUS ANTIBODY AND USES THEREOF - Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable of neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation. | 04-23-2009 |
20090155772 | Method for detecting nanbv associated seroconversion - The present invention relates to recombinant expression vectors which express segments of deoxyribonucleic acid that encode recombinant HIV and HCV antigens. These recombinant expression vectors are transformed into host cells and used in a method to express large quantities of these antigens. The invention also provides compositions containing certain of the isolated antigens, diagnostic systems containing these antigens and methods of assaying body fluids to detect the presence of antibodies against the antigens of the invention. | 06-18-2009 |
20090186046 | Hepatitis C Virus Non Structural Fusion Protein - The present invention relates to an isolated fusion protein comprising at least three NS polypeptides originating from a hepatitis C virus which are configured in said fusion protein in an order which is distinct of the order in which they appear in the native configuration. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof for treating or preventing HCV infections, HCV-associated diseases and pathologic conditions as well as a method of inducing or stimulating an immune response against HCV in a host organism. | 07-23-2009 |
20100008941 | COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE - The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5 | 01-14-2010 |
20110020398 | Novel peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus - The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods. | 01-27-2011 |
20120039938 | COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE - The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application. | 02-16-2012 |
20130011435 | COMPOSITION FOR TREATING HBV INFECTION - The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections. | 01-10-2013 |
20130164250 | METHOD FOR PRODUCTION OF BIORESORBABLE MICROPARTICLES, MICROPARTICLES THUS OBTAINED AND USE THEREOF - Nonlamellar bioresorbable microparticles to which protein substances are bonded, and a method for preparing the microparticles, comprising: (i) preparing the microparticles from at least one bioresorbable polymer without stabilizer and without surfactant; and (ii) bonding the protein substances to the microparticles obtained in step (i) without surfactant. | 06-27-2013 |
Geneviève Loussouarn, Clichy FR
Patent application number | Description | Published |
---|---|---|
20100105741 | ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS - The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, | 04-29-2010 |
Geneviève Loussouarn, Clichy FR
Patent application number | Description | Published |
---|---|---|
20090215837 | ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS - The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, | 08-27-2009 |
20100105741 | ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS - The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, | 04-29-2010 |
20130131095 | ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS - The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, | 05-23-2013 |
Geneviève Renauld-Mongenie, Chaponost FR
Patent application number | Description | Published |
---|---|---|
20100184639 | NUCLEIC ACIDS AND POLYPEPTIDES SPECIFIC OF THE NEISSERIA GENUS PATHOGENIC STRAINS - The invention concerns nucleic acids coding for polypeptides specific of the | 07-22-2010 |
20100330160 | Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 - The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by | 12-30-2010 |
20120156281 | Meningococcal Vaccine Based on Lipooligosaccharide (LOS) and Neisseria Meningitidis Protein - The invention relates to a vaccine against | 06-21-2012 |
Geneviève Renauld-Mongenie, Chaponost FR
Patent application number | Description | Published |
---|---|---|
20090155886 | NUCLEIC ACIDS AND POLYPEPTIDES SPECIFIC FOR PATHOGENIC STRAINS OF THE NEISSERIA GENUS - The invention concerns nucleic acids coding for polypeptides specific of the | 06-18-2009 |
20100184639 | NUCLEIC ACIDS AND POLYPEPTIDES SPECIFIC OF THE NEISSERIA GENUS PATHOGENIC STRAINS - The invention concerns nucleic acids coding for polypeptides specific of the | 07-22-2010 |
20100330160 | Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 - The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by | 12-30-2010 |